BALTIMORE, Aug. 14, 2018 /PRNewswire/ -- Popper and Co., a strategy consulting and transaction advisory firm servingthe needs of the medical technology and life sciences industries, announced today that Co-Founder and President Caroline Popper, M.D., will speak at the 10th Annual Next Generation Dx Summit on August
In the era of precision medicine, it's more important than ever to understand how to apply diagnostic tools efficiently to deliver the right therapy to the right patient at the right time - and to do so cost effectively. During the conference session, entitled "Health Economics of Diagnostics and Immunotherapy," Dr. Popper will highlight a case study examining the economic value of testing a patient's microbiome before commencing immunotherapy. The case study stems from a partnership between Popper and Co. and Monument Analytics that illustrates the value of "Precision Econostics," the firms' new joint offering for biopharmaceutical companies designed to enhance drug adoption through the use of advanced diagnostics.
Precision Econostics utilizes health economic analytic methods and advanced diagnostics expertise to design optimal companion diagnostics strategies for biopharmaceutical clients. To learn more about this unique service, visit www.preconostix.com.
About Next Generation Dx SummitNext Generation Dx Summit has grown to more than 1,000 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its tenth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
About Popper and Co.Popper is a strategy consulting and transaction advisory firm that leverages deep domain expertise and creative thinking to serve the needs of the medical technology and life sciences industries. The company combines leading-edge insights with organizational knowledge to determine where the best opportunities lay to help their clients outmaneuver competitors and accelerate growth. For more information, visit www.popperandco.com.
About Monument AnalyticsMonument is a health care consultancy founded on the premise that the same innovative methods, analytic rigor and scientific acumen associated with the world's leading institutions of higher learning can be delivered in a commercially oriented entity "at the speed of business". Collectively, the company's principals have decades of experience working closely with life sciences companies to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help clients navigate evermore complex regulatory and payment environments.
View original content:http://www.prnewswire.com/news-releases/popper-and-co-to-present-new-framework-for-economic-evaluation-of-diagnostics-in-the-era-of-precision-medicine-at-next-generation-dx-summit-300696704.html
SOURCE Popper and Co.
Subscribe to our Free Newsletters!